Uncategorized Gilead’s twice-yearly shot cut HIV infections by 96% in trial Last updated: September 12, 2024 2:21 pm Share 0 Min Read SHARE The data sets the stage for likely approval of Gilead’s Lenacapavir for HIV prevention. You Might Also Like To fix Starbucks, incoming CEO Brian Niccol will have to tackle its mobile app problem Mars to acquire snack maker Kellanova in $36 billion deal WNBA viewership soars to new record, while attendance hits more than two-decade high Eli Lilly releases new form of weight loss drug Zepbound for half the price to boost access, supply DirecTV, Disney reach deal to end blackout in time for college football Sign Up For Daily NewsletterBe keep up! Get the latest breaking news delivered straight to your inbox.[mc4wp_form]By signing up, you agree to our Terms of Use and acknowledge the data practices in our Privacy Policy. You may unsubscribe at any time. Share This Article Facebook Twitter Copy Link Print Share Previous Article CEO of Ford’s highly profitable Pro business to retire Next Article Airbus Ventures launches $155 million fund focused on deep tech, including space Leave a comment Leave a comment Leave a Reply Cancel replyYour email address will not be published. Required fields are marked *Comment * Name * Email * Website Save my name, email, and website in this browser for the next time I comment. Stay Connected235.3kFollowersLike69.1kFollowersFollow11.6kFollowersPin56.4kFollowersFollow136kSubscribersSubscribe4.4kFollowersFollow - Advertisement - Latest News GM ditching ‘Ultium’ name for batteries, tech amid EV changes Uncategorized October 8, 2024 Boeing delivers 33 jets in September but strike impact looms Uncategorized October 8, 2024 Airlines, theme parks, cruise lines warn travelers about Hurricane Milton disruptions Uncategorized October 8, 2024 Walmart opens five more veterinary and grooming centers, as it makes bigger push in pets Uncategorized October 8, 2024
